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1. Introduction 
Survivin is a member of the inhibitors of apoptosis (IAP) family of highly conserved proteins 
implicated in regulation of mitosis, cytokinesis, cell cycle and apoptosis (Altieri, 2003a; Altieri, 
2003b; Fukuda & Pelus, 2006). It is expressed during development but down regulated in most 
adult tissues. However, Survivin is over-expressed in the majority of solid tumors and 
leukemias, and is usually associated with higher proliferative index, reduced apoptosis, 
resistance to chemotherapy and increased rate of tumor recurrence, making it an attractive 
therapeutic target. We have previously shown that Survivin is expressed and growth factor 
regulated in normal hematopoietic cells and regulates apoptosis and cell cycle entry (Fukuda 
et al., 2002; Fukuda et al., 2004; Fukuda & Pelus, 2001; Fukuda & Pelus, 2002). Antagonizing 
Survivin impairs mouse progenitor cell production in vitro (Fukuda et al., 2002; Fukuda et al., 
2004) and loss of function upon conditional deletion in vivo leads to bone marrow ablation as a 
consequence of loss of stem cell function (Leung et al., 2007). While Survivin is tightly 
regulated in normal hematopoietic cells, deregulated expression is frequently observed in 
hematologic diseases particularly those characterized by stem cell expansion. Survivin is 
aberrantly over expressed in acute myeloid leukemia (Adida et al., 2000; Carter et al., 2001) but 
down regulated in aplastic anemia where hematopoietic stem and progenitor cells are reduced 
(Badran et al., 2003). It is now clear that Survivin can regulate cell growth under both 
physiological and pathological conditions. Therefore, identification of differential signaling 
cascades between normal and abnormal cells downstream of Survivin is required in order to 
identify cancer cell specific targets without toxicity to normal cells.  
2. Survivin mediates aberrant proliferation of hematopoietic progenitor cells 
transformed by ITD-Flt3 
Internal tandem duplication (ITD) mutations of the Flt3 tyrosine kinase receptor are found in 
many patients with acute leukemia, and are an unfavorable prognostic factor (Fukuda et al., 
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2009; Gilliland & Griffin, 2002; Levis et al., 2005). We reported that the combination of Flt3 
ligand (FL), stem cell factor (SCF) and thrombopoietin (TPO) induces Survivin expression in 
human CD34+ cells (Fukuda & Pelus, 2001), suggesting that Survivin lies downstream of Flt3 
signaling. We therefore evaluated the effects of constitutive ITD-Flt3 signaling on Survivin 
expression. Survivin is up regulated by ITD-Flt3 in whole cells, as well as cells in G0/G1 phase 
of the cell cycle (Figure 1) as determined by intracellular flow cytometric analyses. This 
suggests that up regulation of Survivin is not a consequence of cell cycle progression. 
Similarly, Survivin mRNA was up regulated in Ba/F3 cells by ITD-Flt3 compared to wild-type 
Flt3 following IL3 withdrawal. Up regulation of Survivin by ITD-Flt3 was associated with 
growth factor independent proliferation of Ba/F3 cells (Fukuda et al., 2009). We next evaluated 
whether Survivin plays a role in aberrant growth factor-independent primary HPC 
proliferation upon transformation by ITD-Flt3. Over expression of human wild-type Flt3 in 
CFU-GM from control Survivin fx/fx or Survivin fx/fx mice harboring a tamoxifen-inducible Cre 
recombinase (Cre-ERTM) failed to proliferate in vitro, whereas ectopic expression of ITD-Flt3 
resulted in significant growth of CFU-GM in the absence of added growth factors. Treatment 
with 4OH-Tamoxifen to delete Survivin resulted in a significant reduction in the growth 
factor-independent proliferation of CFU-GM induced by ITD-Flt3 (Figure 2). Identical results 
were observed in the immunophenotypically defined c-kit+, Sca-1+, Lineage negative (KSL) 
population of cells enriched for mouse stem and progenitor cells. These findings suggest that 
Survivin is involved in the growth factor-independent proliferation of HPC induced by ITD-
Flt3 and that antagonizing Survivin may be therapeutically beneficial for acute myeloid 
leukemia (AML) expressing ITD-Flt3. 
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Fig. 1. BaF3 cells expressing wild-type Flt3 or ITD-Flt3 were fixed and stained for Survivin 
and DNA in whole cells (left) and cells with 2N DNA representing G0/G1 cells (right).  
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Fig. 2. Wild type Flt3 or ITD-Flt3 were retrovirally transduced into marrow cells from Cre 
ER Survivin fx/fx or control Survivin fx/fx mice. Following transduction, cells were plated in a 
CFU assay in agar with 30% FBS and 1uM 4OH tamoxifen in the absence of hematopoietic 
growth factors for 2 weeks. Treatment with 4OH-TM significantly reduced growth factor 
independent CFU-GM induced by ITD-Flt3 in Cre-ERTM Survivin fx/fx marrow cells. 
3. Survivin regulated genes 
While it is clear that antagonizing Survivin may reduce the aberrant proliferation of 
hematopoietic progenitor cells transformed by ITD-Flt3 and that ITD-Flt3 mutations are 
present in human leukemic stem cells (LSC) (Levis et al., 2005) , studies from our group and 
others indicate that Survivin is a normal regulator of hematopoietic stem and progenitor 
cells (HSPC) (Fukuda et al., 2002; Fukuda et al., 2004; Leung et al., 2007). This suggests that 
Survivin targeted therapies will likely result in hematopoietic toxicity. Therefore, 
identification of differential signaling cascades downstream of Survivin between normal 
HSPC and cancer stem cells (CSC) or LSC are required to pinpoint targets that can 
effectively eradicate CSC/LSC with acceptable toxicity to normal HSPC. In order to identify 
Survivin regulated genes associated with ITD-Flt3 signaling but not normal Flt3 signaling, 
we evaluated human ITD-Flt3 transformed KSL cells from conditional Survivin knockout 
mice as a model of normal and leukemic stem cells. We identified 1096 transcripts 
differentially regulated by Survivin in ITD-Flt3 transformed stem cells [Tables of Survivin 
regulated genes can be found in (Fukuda et al., 2011)]. Classification of these genes based 
upon biological process and molecular function defined by Gene Ontology Term using 
David 2008 showed significant regulation of biological processes, notably phosphate 
metabolic processes, cell cycle, cell division response to DNA stimulus, RNA biosynthetic 
processes and transcription. When evaluated based upon molecular function, iron binding, 
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nucleotide binding, DNA binding and protein kinase activity were the functions most 
significantly affected by Survivin deletion. Although Survivin is known to inhibit caspases 
3, 7 and 10 that mediate apoptosis (Altieri, 2003a; Altieri, 2003b; Fukuda & Pelus, 2006), we 
did not observe significant changes in genes that mediate apoptosis, suggesting that 
Survivin can regulate ITD-Flt3 transformed KSL cell fate independent of its ability to inhibit 
caspase activity. However, microarray analysis was performed on lineage marker negative 
viable cells that express GFP and stem cell markers and survived in culture, perhaps 
explaining lack of effects on genes involved in apoptotic pathways. The finding that 
Survivin deletion affected transcription was surprising since there is no direct evidence that 
Survivin regulates gene transcription. However, this is consistent with the fact that the 
Caenorhabditis elegans Bir1 Survivin homologue regulates transcription, most likely through 
effects on histone phosphorylation by Aurora kinase (Kostrouchova et al., 2003). Survivin is 
essential for activation of Aurora kinase that phosphorylates histone H3 (Bolton et al., 2002; 
Chen et al., 2003), an event required for transcriptional regulation (Cheung et al., 2000; Li et 
al., 2002; Nowak & Corces, 2000) and cytokinesis (Wei et al., 1999). Furthermore, modulation 
of Survivin affects transcription in cancer cells (Asanuma et al., 2004; Balkhi et al., 2008; 
Takizawa et al., 2007) and transgenic Survivin expression alters gene expression in bladder 
cells (Salz et al., 2005). Overexpression of Survivin also leads to phosphorylation of the Sp1 
transcription factor (Asanuma et al., 2004). 
4. Survivin modulates expression of genes deregulated in human AML LSC 
The facts that Survivin is required for the self-renewal of ITD-Flt3 transformed KSL cells and 
ITD-Flt3 is present in leukemic stem cells (LSC) suggests that Survivin is important for LSC 
fate decisions. When the 1,096 differentially expressed genes in Survivin deleted ITD-Flt3+ 
KSL cells was compared with the deregulated gene expression database for human AML 
stem cells (Majeti et al., 2009), 137 genes were identified in common. Survivin deletion 
resulted in down-regulation of 79 genes, while 58 genes were up-regulated, implying that 
these genes are conversely increased and decreased by the presence of Survivin. In contrast, 
92 genes were upregulated and 45 genes were downregulated in LSC. Among the 79 genes 
downregulated by Survivin deletion, 55 were upregulated while 24 genes were 
downregulated in LSC. Among the 58 transcripts upregulated by Survivin deletion, 21 were 
downregulated and 37 upregulated in LSC.  
Classification of these genes into functional annotation groups using DAVID program 
identified significantly (p<0.05) enriched functional groups annotated as phosphoprotein, 
nucleus, acetylation, cell cycle, ATP binding, regulation of EGF signaling pathway, and cell 
adhesion, with a number of genes showing shared function, suggesting enrichment of gene 
groups with redundant function. Among the molecules most frequently shared within the 
functional groups included BGLAP [bone gamma carboxyglutamate protein 1(∆ -10.7)], 
Chrac1 [chromatin accessibility complex 1 (∆ -4.3), Hmgb1 [high mobility group box 1 (∆ -
3.4)] and Smarce1 [SWI ∆ -2.9)]. Phosphoprotein, acetylation, DNA binding, ATP binding 
and DNA replication were significantly enriched when the 76 genes upregulated or 
downregulated both by Survivin deletion and LSC were classified (Figure 3). 
Comparison of the 1,096 differentially Survivin-regulated genes against the mouse HSC 
database (Ivanova et al., 2002) identified 94 differentially expressed genes. This included 45 
genes regulated by Survivin in ITD-Flt3+ HSC whose expression was selectively enriched in 
HSC compared to other populations. Notably, Crem, Emp1, Hmga2, Lrrn1, Maff, Myef2, 
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Rps4x and Sos1 are known to be deregulated in LSC. Comparison of the human LSC 
associated 137 genes regulated by Survivin in ITD-Flt3+KSL cells with differentially 
regulated genes in normal CD34neg KSL cells from control and Survivin deleted mice 
indicated that coincident with reduction of Survivin expression (10-fold in CD34neg KSL cells 
from CreERTM-Survivin fx/fx mice compared to control Survivin fx/fx in two independent 
experiments) out of 137 genes, Arg2, Med25, Pmaip1, Pola2, Ube3b, Ephb2 and Rab18 were 
differentially regulated in both ITD-Flt3+ KSL cells and normal CD34neg KLS cells. In 
contrast, Cenpa, Cpd, Myef2, Nmt2, Taf1b and Tmpo were down regulated in ITD-Flt3+ KSL 
cells while they were upregulated in normal CD34neg KSL cells. These findings suggest that 
124 genes are regulated by Survivin exclusively in ITD-Flt3+ KSL cells but not in normal 
CD34neg  KSL cells (The complete list of the genes regulated by Survivin in CD34neg KSL cells 
will be reported elsewhere). However, these data clearly indicate that Survivin contributes 
to deregulation of gene expression in AML stem cells via effects on selective signaling 
pathways that are distinct from normal HSC that can be potentially targeted for more 
selective anti-Survivin anti-cancer therapies.  
 
 
Fig. 3. Genes regulated in common by Survivin and LSC. The 76 genes up-regulated or 
down regulated by Survivin and LSC were functionally classified by DAVID software. The 
size of each circle represents the number of genes involved in each functional categories and 
the thickness of the line indicates the number of genes shared with any function. Functional 
classification was performed based on Swissprot Keywords. Genes annotated in each 
functional category are shown in the text box. 
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5. Survivin modulates gene expression in LSC that connects through an 
EGFR signaling pathway 
Functional annotation analysis indicates that genes related with dorso-ventral axis formation 
or epidermal growth factor receptor signaling pathway (EGFR) are significantly enriched in 
the shared genes associated with LSC and Survivin signaling in the KEGG database 
(http://www.genome.jp/kegg/) (P<0.03). Similarly, genes associated with regulation of 
EGFR signaling pathway are enriched in the Gene Ontology database (P<0.02). Our analysis 
shows that molecules shared by LSC and Survivin signaling are mapped on a functional 
signaling network that connects through the EGFR pathway (Figure 4). EGFR signaling  
 
 
Fig. 4. Genes regulated by Survivin in ITD-Flt3+ KSL cells and deregulated in LSC are 
mapped on a functional signaling network associated with the epidermal growth factor 
receptor signaling pathway. Epidermal growth factor receptor signaling pathway (EGFR) 
is significantly enriched in the shared genes associated with LSC and Survivin signaling 
by pathway enrichment analysis in KEGG and Gene Ontology databases. Our analysis 
shows that 13 molecules shared by LSC and Survivin signaling are mapped on a 
functional signaling network associated with EGFR. The network was created based on 
the KEGG database using Cytoscape software. Gray and black circle represents down 
regulation and up regulation by Survivin gene deletion, respectively. The hatched circle 
shows EGFR. 
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activates signaling cascades involved in cell proliferation, such as Src, Sos and MAP-kinases 
and is known to be dysregulated in a number of solid tumors (Alvarez et al., 2010; Harris & 
McCormick, 2010). These findings suggest a potential role of EGFR signaling downstream of 
Survivin in AML stem cells, despite the fact that EGFR is not usually up regulated in AML 
cells (Hahn et al., 2009). However, recent studies indicate an anti-neoplastic effect of an 
EGFR inhibitor in AML via off-target effects (Boehrer et al., 2008; Hahn et al., 2009). Thus, 
our data would support EGFR signaling as a candidate pathway for treatment of patients 
with AML, even though the number of molecules detected that associates with EGFR 
signaling is small. 
6. Survivin splice variants 
Survivin, like many genes, is alternatively spliced and variants having both similar or 
opposite activities have been identified, some of which are of prognostic significance 
(Fukuda & Pelus, 2006; Sampath & Pelus, 2007) . Spliced variants identified to date include 
Survivin 2 (Caldas et al., 2005; Mahotka et al., 2002) , 2B, Ex3 (Ling et al., 2005; Mahotka et 
al., 1999; Mahotka et al., 2002; Song & Wu, 2005) and 3B (Badran et al., 2004), and some of 
these variants have been evaluated for their anti- or pro-apoptotic function and ability to 
interact with wild-type Survivin and other chromosomal passenger proteins (CPC) in some 
model systems. More recently, several new Survivin splice variants were found in the 
expressed sequence tag (est) database or described based on RT-PCR using RNA from Molt-
4 cells (Li & Ling, 2006; Mola et al., 2007), however the biological functions of these new 
variants are not known. Overall, with most all the variants reported to date, there is still a 
considerable lack of understanding of their biology and their function and prognostic value 
is only now being realized (Sampath & Pelus, 2007). In order to better understand the 
biology of human Survivin splice variants, we cloned each variant and evaluated their 
antiapoptotic functions. In the process, we identified a new splice variant we termed 
Survivin 3 that is similar to Survivin 3B (Figure 5). To determine if this was truly a novel 
variant, a forward primer specific for all splice variants and a splice variant specific reverse 
primer were designed and used to amplify cDNA using a polydT reverse transcribed cDNA 
library from HL60, K562 and Mo7e-Bcr-abl cells, the products resolved on an agarose gel 
and ~400bp bands excised, cloned and sequenced. Sequence analysis confirmed the 
presence of the novel splice variant. Survivin 3 contains 12 new amino acids at the C-
terminus compared to wild-type Survivin and differs from all of the previously reported 
Survivin splice variants. Secondary structure prediction using Jpred suggests that Survivin 
3 is structurally similar to wild-type Survivin, with the new amino acids predicted to be 
capable of forming a C-terminal helix that could potentially form the coiled coil domain, 
even though the length of this helix would be smaller than wild-type Survivin.  
7. Expression of Survivin 3γ 
Survivin 3 expression in primary cancer tissues was determined by quantitative RT-PCR on 
primary breast and prostate tumor samples obtained in an array format. In contrast to most 
cancers where wild-type Survivin is the predominant transcript, Survivin 3 was expressed 
at higher levels in benign prostate tissue and at equivalent levels in breast cancer cells. In 
primary breast cancer samples a statistically significant increase in wild-type Survivin 
expression at stages 1, 2 and 3 compared to control normal breast tissue was observed, with 
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no significant difference observed between wild-type Survivin expression at stage 1 
compared to later stages. In 7 normal breast tissue samples wild-type Survivin and Survivin 
3 were expressed at the same level. However, in contrast to expression of wild-type 
Survivin, Survivin 3 expression remained relatively constant at all stages of disease, 
resulting in statistically significant (p<0.005) lower relative expression to wild-type Survivin.  
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Fig. 5. Agarose gel electrophoresis of cDNA amplified from HL60 cells (lane 2). The 
Survivin-3B variant is indicated by a solid arrow, the dotted arrow points to the slower 
migrating band. Amino acid sequence of Survivin-3 is shown on the right. Bold letters 
indicate novel sequence distinct from wild-type Survivin. The stop codon is indicated by the *. 
In 48 prostate cancers at different stages of the disease, wild-type Survivin expression was 
higher in stage 1 prostate cancer compared to benign hyperplasia; however sample size was 
too small to evaluate statistical significance. No clear over-expression of wild-type Survivin 
was seen at higher stages, except for a single stage 4 sample. The expression of Survivin 3 
was higher than wild-type Survivin in benign hyperplasia tissue and comparison of the 
relative expression of wild-type Survivin and Survivin 3 at each stage of prostate cancer 
indicated that Survivin 3 transcripts remained higher than wild-type Survivin at all stages 
except stage 1. To our knowledge, the higher expression of Survivin 3 in benign prostate 
hyperplasia is the first demonstration of a Survivin splice variant expressed at higher levels 
than wild-type Survivin and suggest that it may play a role in normal cell function. 
The finding that Survivin 3 expression was higher than wild-type Survivin in benign 
prostate hyperplasia (BPH) samples and did not change with stage of disease is consistent 
with one study (Kaur et al., 2004) where Survivin expression was detected by 
immunohistochemistry. However, other reports show increased Survivin with stage of 
disease either at the RNA level by standard RT-PCR and gel electrophoresis (Kishi et al., 
2004; Krajewska et al., 2003) or by immunohistochemistry (Krajewska et al., 2003). The 
difference between our study and those reported using standard RT-PCR could be due to 
differences in sensitivity of the method used. SYBR green quantitative RT-PCR is more 
sensitive and efficient in amplifying smaller amplicons than conventional RT-PCR. We also 
show that expression of wild-type Survivin and Survivin 3 were comparable in normal 
www.intechopen.com
Survivin: Identification of Selective Functional Signaling Pathways 
in Transformed Cells and Identification of a New Splice Variant with Growth Survival Activity 
 
195 
breast tissues and that the expression of Survivin increased at stage 1 and remained high at 
all stages, whereas a recent report (Sohn et al., 2006) showed Survivin expression increased 
gradually at all disease stages. This difference could again be due to different methodologies 
and sensitivity between RNA analyses versus immunohistochemistry. Since the Survivin 3 
splice variant was identified in the human HL-60 promyelocytic cell line, we evaluated its 
expression in other hematopoietic cells by quantitative RT-PCR using SYBR Green. While 
wild-type Survivin was the predominant transcript identified in all cell lines tested, Survivin 
3 transcripts represented ~0.7-6% of the total Survivin transcripts detected. The absolute 
expression of Survivin 3 was lowest in growth factor dependant cells and highest in growth 
factor independent cells. Analysis of Survivin 3 in primary umbilical cord blood (UCB) 
CD34+ cells that are enriched for hematopoietic stem and progenitor cells showed that 
Survivin 3 was expressed at significantly higher levels than wild-type Survivin. This is in 
contrast to most splice variants that are expressed at lower levels than wild-type Survivin in 
these cells. However, growth factor stimulation induced a dramatic increase in expression of 
wild-type Survivin after 48 hours consistent with our previous findings (Fukuda et al., 2002; 
Fukuda & Pelus, 2001; Fukuda & Pelus, 2002), whereas the expression of Survivin 3 
increased only slightly, therefore relative levels compared to wild-type Survivin decreased 
by ~2-fold. This suggests perhaps that Survivin 3 may play a role in hematopoietic stem 
cell maintenance. 
8. Survivin 3γdemonstrates antiapoptotic activity  
To evaluate the function of the novel Survivin 3 splice variants, we stably expressed human 
(Hu) wild-type Survivin with or without an N-terminal Flag-tag or Survivin 3 with an N-
terminal HA-tag in murine YAC-1 lymphoma cells. Wild-type HuSurvivin, wild-type Flag-
HuSurvivin and HA-Survivin 3 were all expressed, although their levels of expression 
varied, with wild-type HuSurvivin expressing at 31-fold, whereas wild-type Flag-
HuSurvivin and HA-Survivin 3 were expressed at 76- and 63-fold higher levels, 
respectively than the empty vector control cells at the RNA level. Western blot analysis 
using a rabbit anti-Survivin polyclonal antibody that recognizes both the human and the 
murine Survivin showed background levels of murine Survivin as well as the presence of 
each of the transduced Survivins, indicating that each of the splice variants was translated. 
Analysis of band intensity indicated that wild-type HuSurvivin was expressed at the highest 
level followed by wild-type Flag-HuSurvivin with HA-Survivin 3 expressed at a lower 
level. The same pattern of expression was observed with a mouse anti-Survivin monoclonal 
antibody that recognizes predominantly human Survivin. 
As a measure of anti-apoptotic function we evaluated resistance of YAC-1 cells transduced 
with wild-type Survivin, wild-type Flag-Survivin and HA-Survivin 3 to the 
chemotherapeutic drugs Etoposide and Taxol at their optimal therapeutic dose. Treatment 
of cells with Taxol showed that, as expected, over expression of either wild-type Survivin or 
wild-type Flag-Survivin provided 2.7- and 2.8-fold resistance to Taxol-induced cell death, 
respectively, compared to YAC-1 cells transduced with vector control (Figure 6). Ectopic 
expression of HA-Survivin 3 provided 2.6-fold resistance. In multiple experiments, the 
IC50’s for wild-type HuSurvivin, wild-type Flag-HuSurvivin and HA-Survivin 3 were 
significantly higher than control (2.85 ± 0.32; P<0.05). YAC-1 cells expressing wild-type 
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Survivin also showed significant resistance to Etoposide. Wild-type Flag-Survivin and HA-
Survivin 3 conferred resistance to Etoposide in YAC-1 cells to a similar degree as wild-type 
Survivin. These studies suggest that expression of Survivin 3 could potentially contribute to 
drug resistance. Expression levels of murine wild-type Survivin and the only known murine 
Survivin splice variant, Survivin-121 (Conway et al., 2000) were unchanged (not shown), 
indicating that changes in endogenous murine Survivin levels were not involved in the 
increase in resistance to chemotherapeutic compounds. These findings suggest that wild-
type and Survivin 3 proteins possess equivalent anti-apoptotic function. Since crystal 
structure of wild-type Survivin indicates that the C-terminal helix could be involved in 
protein-protein interaction (Chantalat et al., 2000) and required for interaction with the 
chromosomal passenger protein, INCEP (Wheatley et al., 2004), whereas the N-terminus of 
wild-type Survivin was unordered (Chantalat et al., 2000), we hypothesized that addition of 
a C-terminal tag would hinder protein-protein interactions, therefore we engineered N-
terminal tags into all the Survivin cDNAs. The presence of HA-tag at the N-terminus of the 
Survivin coding region did not affect activity since they were equivalent to N-terminal Flag-
tagged wild-type Survivin, which itself behaved similar to wild-type Survivin at least for 
drug sensitivity. The facts that Survivin 3confers drug resistance/anti-apoptotic function 
to two different classes of chemotherapeutic drugs Taxol, a microtubule destabilizing agent, 
and Etoposide, a topoisomerase II inhibitor, as well as growth factor independence similar 
to wild-type Survivin, and that it may be preferentially associated with maintenance of stem 
cell quiescence, makes it an interesting potential therapeutic target . 
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Fig. 6. Response of YAC1 cells over expressing wild-type human Survivin (SurWT),  
wild-type human Flag-Survivin (Flag-Sur WT) and HA Survivin 3 (HA-Sur3) to 
chemotherapeutic drugs. Fold resistance of stable transduced YAC-1 cells treated with 50 
nM Taxol or 0.25 µg/ml Etoposide. 
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9. Summary 
We have shown that ITD-Flt3 mutations increase expression of Survivin, which regulates 
development of ITD-Flt3+ acute leukemia, clearly indicating a potential therapeutic benefit 
for antagonizing Survivin in patients with ITD-Flt3+ AML (Fukuda et al., 2009; Fukuda et al., 
2011; Sampath & Pelus, 2007). However, we have shown that Survivin also regulates normal 
HSPC function (Fukuda et al., 2004; Fukuda & Pelus, 2002; Leung et al., 2007; Sampath & 
Pelus, 2007); raising caution that targeting Survivin can have hematopoietic toxicity. 
Therefore, identification of differential signaling cascades downstream of Survivin between 
normal hematopoietic cells versus cancer and leukemia stem cells is required to pinpoint 
targets that can lead to effective anti-malignant therapies with acceptable normal stem cell 
toxicity. Our genetic profiling using normal and ITD-Flt3 transformed cells from conditional 
Survivin knockout mice has identified a panel of genes that are specifically regulated by 
Survivin in ITD-Flt3 transformed cells and known to be deregulated in human LSC that can 
be potentially targeted for selective anti-leukemia therapy. 
Inherited and acquired changes in pre-mRNA splicing have been documented to play a 
significant role in human disease development and loss of fidelity or variation of the 
splicing process may play a major role in carcinogenesis (Fackenthal & Godley, 2008; Matlin 
et al., 2005; Skotheim & Nees, 2007) . Splice variants that are found predominantly in tumors 
have clear diagnostic value (Brinkman, 2004; Caballero et al., 2001) and may provide 
potential drug targets. Splice variants of Survivin have been reported but their prognostic 
value is not clear, partially based upon detection methods that are not sufficiently specific 
(Sampath & Pelus, 2007), or due to lack of information on biological function. We have 
identified a novel Survivin splice variant with anti-apoptotic activity similar to wild-type 
Survivin, at least with respect to sensitivity to chemotherapeutic drugs. We characterized its 
expression in several transformed cell lines, and similar to other Survivin splice variants, 
wild-type Survivin is the predominant transcript. However, in contrast to wild-type 
Survivin, Survivin 3 expression does not change with increasing stage/severity of primary 
prostate and breast cancers. In addition, unlike other Survivin splice variants, Survivin 3 is 
expressed at higher levels than wild-type Survivin in primary HSPC, and their lack of 
increase with cell proliferation suggests that they may play a role in stem cell maintenance. 
Since Survivin 3 was cloned from and found to be highly expressed in hematopoietic cells, 
it will be particularly interesting to evaluate its expression in hematopoietic malignancies 
and their correlation with disease/stage/survival. Furthermore, since ITD-Flt3 mutations 
increase Survivin expression, it will be interesting to determine if they also modulate 
Survivin 3 expression and how this relates to disease progression and prognostic value. 
Given the specific genes regulated by Survivin in leukemic stem cells, it will also be of 
interest whether Survivin 3 elicits overlapping or divergent gene products that can be 
utilized for development of anti-leukemia therapies.  
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